Cardiff Oncology, Inc. (CRDF) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.21 |
| Open | 1.27 |
| Day High | 1.43 |
| Day Low | 1.27 |
| 52-Week High | 4.56 |
| 52-Week Low | 1.16 |
| Volume | 1.06M |
| Average Volume | 1.08M |
| Market Cap | 88.88M |
| PE | -1.94 |
| EPS | -0.67 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 2.02 |
| Change | 0.09 |
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 26, 2026 9:01 PM GMT
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
GlobeNewswire Inc.
Jan 27, 2026 12:05 PM GMT
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selec